Ryota Akazawa, K. Maeda, Y. Yoshitomi, T. Fujiwara, Yoshikazu Watanabe, Tomoki Shokawa, S. Tsujiyama, T. Fujii
{"title":"顺行球囊主动脉瓣成形术在低流量、低梯度主动脉瓣狭窄和st段抬高型心肌梗死患者中的作用","authors":"Ryota Akazawa, K. Maeda, Y. Yoshitomi, T. Fujiwara, Yoshikazu Watanabe, Tomoki Shokawa, S. Tsujiyama, T. Fujii","doi":"10.7793/JCAD.27.20-00033","DOIUrl":null,"url":null,"abstract":"Selecting an appropriate therapeutic strategy for severe aortic stenosis (AS) is challenging in presence of ST-elevation myocardial infarction (STEMI). We report a case in which antegrade balloon aortic valvuloplasty (A-BAV) played an important role in temporizing a patient with severe AS and reduced left ventricular ejection fraction (LVEF) due to STEMI. Our patient was an 85-year-old man who experienced anterior STEMI (peak creatine kinase = 5286 U/L) and fulfilled the criteria of classical LFLG-AS (aortic valve area = 0.68 cm 2 , LVEF = 16%, and MPG = 20 mmHg). He had heart failure symptoms refractory to optimized therapy, including intra-aortic balloon pump (IABP) counterpulsation, even after successful recanalization of the coronary artery. Intervention for severe AS was required; however, the patient was identified to be at high risk for surgery (Society of Thoracic Surgeons score = 16.56%), and our hospital is not a transcatheter aortic valve replacement-capable facility. We performed A-BAV for hemodynamic restoration. A few days after successful A-BAV, tapering of norepinephrine and weaning of IABP were initiated. A cardiac rehabilitation program was initiated during the intensive care period, and which facilitated the patient to be discharged. A-BAV achieved convalescence with no recurrence of heart failure hospitalization at 510 days of follow-up.","PeriodicalId":73692,"journal":{"name":"Journal of coronary artery disease","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Role of Antegrade Balloon Aortic Valvuloplasty in a Patient with Low-flow, Low-gradient Aortic Stenosis and ST-elevation Myocardial Infarction\",\"authors\":\"Ryota Akazawa, K. Maeda, Y. Yoshitomi, T. Fujiwara, Yoshikazu Watanabe, Tomoki Shokawa, S. Tsujiyama, T. Fujii\",\"doi\":\"10.7793/JCAD.27.20-00033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Selecting an appropriate therapeutic strategy for severe aortic stenosis (AS) is challenging in presence of ST-elevation myocardial infarction (STEMI). We report a case in which antegrade balloon aortic valvuloplasty (A-BAV) played an important role in temporizing a patient with severe AS and reduced left ventricular ejection fraction (LVEF) due to STEMI. Our patient was an 85-year-old man who experienced anterior STEMI (peak creatine kinase = 5286 U/L) and fulfilled the criteria of classical LFLG-AS (aortic valve area = 0.68 cm 2 , LVEF = 16%, and MPG = 20 mmHg). He had heart failure symptoms refractory to optimized therapy, including intra-aortic balloon pump (IABP) counterpulsation, even after successful recanalization of the coronary artery. Intervention for severe AS was required; however, the patient was identified to be at high risk for surgery (Society of Thoracic Surgeons score = 16.56%), and our hospital is not a transcatheter aortic valve replacement-capable facility. We performed A-BAV for hemodynamic restoration. A few days after successful A-BAV, tapering of norepinephrine and weaning of IABP were initiated. A cardiac rehabilitation program was initiated during the intensive care period, and which facilitated the patient to be discharged. A-BAV achieved convalescence with no recurrence of heart failure hospitalization at 510 days of follow-up.\",\"PeriodicalId\":73692,\"journal\":{\"name\":\"Journal of coronary artery disease\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of coronary artery disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7793/JCAD.27.20-00033\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of coronary artery disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7793/JCAD.27.20-00033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Role of Antegrade Balloon Aortic Valvuloplasty in a Patient with Low-flow, Low-gradient Aortic Stenosis and ST-elevation Myocardial Infarction
Selecting an appropriate therapeutic strategy for severe aortic stenosis (AS) is challenging in presence of ST-elevation myocardial infarction (STEMI). We report a case in which antegrade balloon aortic valvuloplasty (A-BAV) played an important role in temporizing a patient with severe AS and reduced left ventricular ejection fraction (LVEF) due to STEMI. Our patient was an 85-year-old man who experienced anterior STEMI (peak creatine kinase = 5286 U/L) and fulfilled the criteria of classical LFLG-AS (aortic valve area = 0.68 cm 2 , LVEF = 16%, and MPG = 20 mmHg). He had heart failure symptoms refractory to optimized therapy, including intra-aortic balloon pump (IABP) counterpulsation, even after successful recanalization of the coronary artery. Intervention for severe AS was required; however, the patient was identified to be at high risk for surgery (Society of Thoracic Surgeons score = 16.56%), and our hospital is not a transcatheter aortic valve replacement-capable facility. We performed A-BAV for hemodynamic restoration. A few days after successful A-BAV, tapering of norepinephrine and weaning of IABP were initiated. A cardiac rehabilitation program was initiated during the intensive care period, and which facilitated the patient to be discharged. A-BAV achieved convalescence with no recurrence of heart failure hospitalization at 510 days of follow-up.